CA2425434A1 - Methods for characterizing molecular interactions using affinity capture tandem mass spectrometry - Google Patents
Methods for characterizing molecular interactions using affinity capture tandem mass spectrometry Download PDFInfo
- Publication number
- CA2425434A1 CA2425434A1 CA002425434A CA2425434A CA2425434A1 CA 2425434 A1 CA2425434 A1 CA 2425434A1 CA 002425434 A CA002425434 A CA 002425434A CA 2425434 A CA2425434 A CA 2425434A CA 2425434 A1 CA2425434 A1 CA 2425434A1
- Authority
- CA
- Canada
- Prior art keywords
- binding partner
- binding
- probe
- protein
- affinity capture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 164
- 230000004001 molecular interaction Effects 0.000 title abstract description 5
- 238000004885 tandem mass spectrometry Methods 0.000 title description 23
- 239000000523 sample Substances 0.000 claims abstract description 267
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 162
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 162
- 238000001698 laser desorption ionisation Methods 0.000 claims abstract description 38
- 238000009739 binding Methods 0.000 claims description 208
- 230000027455 binding Effects 0.000 claims description 206
- 235000018102 proteins Nutrition 0.000 claims description 157
- 150000002500 ions Chemical class 0.000 claims description 119
- 239000012634 fragment Substances 0.000 claims description 64
- 238000004458 analytical method Methods 0.000 claims description 39
- 108020003175 receptors Proteins 0.000 claims description 39
- 102000005962 receptors Human genes 0.000 claims description 39
- 230000003993 interaction Effects 0.000 claims description 34
- 238000001179 sorption measurement Methods 0.000 claims description 32
- 238000005259 measurement Methods 0.000 claims description 22
- 238000001819 mass spectrum Methods 0.000 claims description 18
- 239000012071 phase Substances 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 16
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- 238000001360 collision-induced dissociation Methods 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 238000003776 cleavage reaction Methods 0.000 claims description 12
- 230000007017 scission Effects 0.000 claims description 12
- 241000206602 Eukaryota Species 0.000 claims description 10
- 108091005804 Peptidases Proteins 0.000 claims description 10
- 239000012472 biological sample Substances 0.000 claims description 10
- 238000010828 elution Methods 0.000 claims description 10
- 229910052751 metal Inorganic materials 0.000 claims description 10
- 239000002184 metal Substances 0.000 claims description 10
- 230000003100 immobilizing effect Effects 0.000 claims description 9
- 238000001228 spectrum Methods 0.000 claims description 9
- 239000004365 Protease Substances 0.000 claims description 8
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 108090000288 Glycoproteins Proteins 0.000 claims description 7
- 102000003886 Glycoproteins Human genes 0.000 claims description 7
- 108090000631 Trypsin Proteins 0.000 claims description 7
- 102000004142 Trypsin Human genes 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 239000011616 biotin Substances 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 239000012588 trypsin Substances 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 108091023040 Transcription factor Proteins 0.000 claims description 6
- 102000040945 Transcription factor Human genes 0.000 claims description 6
- 238000005349 anion exchange Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 230000009149 molecular binding Effects 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 238000001877 single-ion monitoring Methods 0.000 claims description 6
- 108090001008 Avidin Proteins 0.000 claims description 5
- 108090001090 Lectins Proteins 0.000 claims description 5
- 102000004856 Lectins Human genes 0.000 claims description 5
- 101710118538 Protease Proteins 0.000 claims description 5
- 108010090804 Streptavidin Proteins 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 238000004891 communication Methods 0.000 claims description 5
- 230000006854 communication Effects 0.000 claims description 5
- 239000002523 lectin Substances 0.000 claims description 5
- 230000002441 reversible effect Effects 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 108010059339 submandibular proteinase A Proteins 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 108091008874 T cell receptors Proteins 0.000 claims description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 239000013592 cell lysate Substances 0.000 claims description 4
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 4
- 210000002751 lymph Anatomy 0.000 claims description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 3
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 3
- 241000282414 Homo sapiens Species 0.000 claims description 3
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 claims description 3
- 102000012479 Serine Proteases Human genes 0.000 claims description 3
- 108010022999 Serine Proteases Proteins 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 239000013060 biological fluid Substances 0.000 claims description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical group C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 3
- 125000003700 epoxy group Chemical group 0.000 claims description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 239000010931 gold Substances 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 108010031896 Cell Cycle Proteins Proteins 0.000 claims description 2
- 102000005483 Cell Cycle Proteins Human genes 0.000 claims description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 2
- 102100021238 Dynamin-2 Human genes 0.000 claims description 2
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 claims description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 2
- 102000002278 Ribosomal Proteins Human genes 0.000 claims description 2
- 108010000605 Ribosomal Proteins Proteins 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 210000001742 aqueous humor Anatomy 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 239000004031 partial agonist Substances 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000001179 synovial fluid Anatomy 0.000 claims description 2
- 210000004127 vitreous body Anatomy 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
- 241000283984 Rodentia Species 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 241000251468 Actinopterygii Species 0.000 claims 1
- 241000700199 Cavia porcellus Species 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 241000244206 Nematoda Species 0.000 claims 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 1
- 241000592342 Tracheophyta Species 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 108020004017 nuclear receptors Proteins 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 102000027257 transmembrane receptors Human genes 0.000 claims 1
- 108091008578 transmembrane receptors Proteins 0.000 claims 1
- 238000012512 characterization method Methods 0.000 abstract description 4
- 239000007789 gas Substances 0.000 description 53
- 238000003795 desorption Methods 0.000 description 50
- 108090000765 processed proteins & peptides Proteins 0.000 description 49
- 238000004949 mass spectrometry Methods 0.000 description 44
- 238000013459 approach Methods 0.000 description 30
- 230000003287 optical effect Effects 0.000 description 30
- 102000004196 processed proteins & peptides Human genes 0.000 description 30
- 239000012491 analyte Substances 0.000 description 29
- 239000003463 adsorbent Substances 0.000 description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 23
- 230000008901 benefit Effects 0.000 description 20
- 239000013307 optical fiber Substances 0.000 description 20
- 230000009870 specific binding Effects 0.000 description 20
- 239000000047 product Substances 0.000 description 16
- 230000005284 excitation Effects 0.000 description 15
- 239000000835 fiber Substances 0.000 description 15
- 239000003446 ligand Substances 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 230000000717 retained effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 108010033276 Peptide Fragments Proteins 0.000 description 11
- 102000007079 Peptide Fragments Human genes 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 238000013467 fragmentation Methods 0.000 description 11
- 238000006062 fragmentation reaction Methods 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 206010060862 Prostate cancer Diseases 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000001133 acceleration Effects 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 238000005065 mining Methods 0.000 description 8
- 230000007026 protein scission Effects 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 102000035195 Peptidases Human genes 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000013461 design Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000009878 intermolecular interaction Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000002797 proteolythic effect Effects 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 238000000018 DNA microarray Methods 0.000 description 5
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 5
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 5
- 238000011948 assay development Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005040 ion trap Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 239000000091 biomarker candidate Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000009510 drug design Methods 0.000 description 4
- 238000000132 electrospray ionisation Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000004304 visual acuity Effects 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 229920001222 biopolymer Polymers 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229910052756 noble gas Inorganic materials 0.000 description 3
- 150000002835 noble gases Chemical class 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- -1 phosphorotriesters Chemical class 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Natural products OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- 229910052691 Erbium Inorganic materials 0.000 description 2
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102400000868 Seminal basic protein Human genes 0.000 description 2
- 101800001987 Seminal basic protein Proteins 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- AFVLVVWMAFSXCK-VMPITWQZSA-N alpha-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(\C#N)=C\C1=CC=C(O)C=C1 AFVLVVWMAFSXCK-VMPITWQZSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000003766 bioinformatics method Methods 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001977 collision-induced dissociation tandem mass spectrometry Methods 0.000 description 2
- 230000002153 concerted effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 230000009120 phenotypic response Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 230000018448 secretion by cell Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000000107 tumor biomarker Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- KEJYUAMBFQZVEH-UHFFFAOYSA-N 3-cyano-2-hydroxy-3-phenylprop-2-enoic acid Chemical compound OC(=O)C(O)=C(C#N)C1=CC=CC=C1 KEJYUAMBFQZVEH-UHFFFAOYSA-N 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000582786 Monoplex Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102100037550 Semenogelin-1 Human genes 0.000 description 1
- 101710089345 Semenogelin-1 Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000007813 chromatographic assay Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000021040 cytoplasmic transport Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005421 electrostatic potential Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 102000013361 fetuin Human genes 0.000 description 1
- 108060002885 fetuin Proteins 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000000534 ion trap mass spectrometry Methods 0.000 description 1
- 230000005596 ionic collisions Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000011034 membrane dialysis Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 238000000955 peptide mass fingerprinting Methods 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 1
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6818—Sequencing of polypeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
- G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/004—Combinations of spectrometers, tandem spectrometers, e.g. MS/MS, MSn
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/02—Details
- H01J49/10—Ion sources; Ion guns
- H01J49/16—Ion sources; Ion guns using surface ionisation, e.g. field-, thermionic- or photo-emission
- H01J49/161—Ion sources; Ion guns using surface ionisation, e.g. field-, thermionic- or photo-emission using photoionisation, e.g. by laser
- H01J49/164—Laser desorption/ionisation, e.g. matrix-assisted laser desorption/ionisation [MALDI]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Optics & Photonics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Plasma & Fusion (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/028261 WO2002031484A2 (en) | 2000-10-11 | 2000-10-11 | Methods for characterizing molecular interactions using affinity capture tandem mass spectrometry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2425434A1 true CA2425434A1 (en) | 2002-04-18 |
Family
ID=21741885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002425434A Abandoned CA2425434A1 (en) | 2000-10-11 | 2000-10-11 | Methods for characterizing molecular interactions using affinity capture tandem mass spectrometry |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20030219731A1 (enExample) |
| EP (1) | EP1327151A2 (enExample) |
| JP (1) | JP2004511773A (enExample) |
| CN (1) | CN1474944A (enExample) |
| AU (1) | AU1199501A (enExample) |
| CA (1) | CA2425434A1 (enExample) |
| WO (1) | WO2002031484A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0101555D0 (sv) * | 2001-05-04 | 2001-05-04 | Amersham Pharm Biotech Ab | Fast variable gain detector system and method of controlling the same |
| US6946653B2 (en) * | 2001-11-27 | 2005-09-20 | Ciphergen Biosystems, Inc. | Methods and apparatus for improved laser desorption ionization tandem mass spectrometry |
| US7846748B2 (en) * | 2002-12-02 | 2010-12-07 | The University Of North Carolina At Chapel Hill | Methods of quantitation and identification of peptides and proteins |
| CN1314968C (zh) * | 2004-03-11 | 2007-05-09 | 复旦大学 | 痕量多肽或蛋白质富集及其直接分析方法 |
| CN100376895C (zh) * | 2004-11-03 | 2008-03-26 | 中国科学院计算技术研究所 | 一种使用串联质谱数据鉴定肽的方法 |
| CN100483394C (zh) * | 2006-04-14 | 2009-04-29 | 中国科学院计算技术研究所 | 一种质谱数据处理中噪音基线识别方法 |
| US7879799B2 (en) * | 2006-08-10 | 2011-02-01 | Institute For Systems Biology | Methods for characterizing glycoproteins and generating antibodies for same |
| EP3511973B1 (en) * | 2010-12-28 | 2021-08-04 | Quest Diagnostics Investments LLC | Quantitation of insulin by mass spectrometry |
| GB201110272D0 (en) | 2011-06-17 | 2011-08-03 | Isis Innovation | Metod of detection by mass spectrometry |
| CN203367223U (zh) * | 2012-05-21 | 2013-12-25 | 核工业北京地质研究院 | 热电离飞行时间质谱仪 |
| WO2015189749A1 (en) * | 2014-06-13 | 2015-12-17 | Dh Technologies Development Pte. Ltd. | Methods for analysis of lipids using mass spectrometry |
| CA2966315A1 (en) * | 2014-10-30 | 2016-05-06 | Dh Technologies Development Pte. Ltd. | Methods and systems for selecting ions for ion fragmentation |
| US10049868B2 (en) * | 2016-12-06 | 2018-08-14 | Rapiscan Systems, Inc. | Apparatus for detecting constituents in a sample and method of using the same |
| CN114383984B (zh) * | 2021-12-06 | 2022-09-23 | 浙江大学 | 一种捕获颗粒物并测量其相态、形貌和化学组分的系统 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288644A (en) * | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5202563A (en) * | 1991-05-16 | 1993-04-13 | The Johns Hopkins University | Tandem time-of-flight mass spectrometer |
| US5144127A (en) * | 1991-08-02 | 1992-09-01 | Williams Evan R | Surface induced dissociation with reflectron time-of-flight mass spectrometry |
| US5382793A (en) * | 1992-03-06 | 1995-01-17 | Hewlett-Packard Company | Laser desorption ionization mass monitor (LDIM) |
| ATE242485T1 (de) * | 1993-05-28 | 2003-06-15 | Baylor College Medicine | Verfahren und massenspektrometer zur desorption und ionisierung von analyten |
| US6020208A (en) * | 1994-05-27 | 2000-02-01 | Baylor College Of Medicine | Systems for surface-enhanced affinity capture for desorption and detection of analytes |
| US6017693A (en) * | 1994-03-14 | 2000-01-25 | University Of Washington | Identification of nucleotides, amino acids, or carbohydrates by mass spectrometry |
| US5498545A (en) * | 1994-07-21 | 1996-03-12 | Vestal; Marvin L. | Mass spectrometer system and method for matrix-assisted laser desorption measurements |
| US5777324A (en) * | 1996-09-19 | 1998-07-07 | Sequenom, Inc. | Method and apparatus for maldi analysis |
| NZ516848A (en) * | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
| GB9717926D0 (en) * | 1997-08-22 | 1997-10-29 | Micromass Ltd | Methods and apparatus for tandem mass spectrometry |
| US6348688B1 (en) * | 1998-02-06 | 2002-02-19 | Perseptive Biosystems | Tandem time-of-flight mass spectrometer with delayed extraction and method for use |
| US6428956B1 (en) * | 1998-03-02 | 2002-08-06 | Isis Pharmaceuticals, Inc. | Mass spectrometric methods for biomolecular screening |
| US6723564B2 (en) * | 1998-05-07 | 2004-04-20 | Sequenom, Inc. | IR MALDI mass spectrometry of nucleic acids using liquid matrices |
-
2000
- 2000-10-11 CA CA002425434A patent/CA2425434A1/en not_active Abandoned
- 2000-10-11 EP EP00973492A patent/EP1327151A2/en not_active Withdrawn
- 2000-10-11 WO PCT/US2000/028261 patent/WO2002031484A2/en not_active Ceased
- 2000-10-12 AU AU1199501A patent/AU1199501A/xx active Pending
- 2000-10-12 CN CNA008199639A patent/CN1474944A/zh active Pending
- 2000-10-12 JP JP2002534819A patent/JP2004511773A/ja active Pending
-
2003
- 2003-04-01 US US10/406,023 patent/US20030219731A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20030219731A1 (en) | 2003-11-27 |
| WO2002031484A2 (en) | 2002-04-18 |
| AU1199501A (en) | 2002-04-22 |
| WO2002031484A8 (en) | 2003-09-04 |
| WO2002031484A3 (en) | 2002-07-25 |
| JP2004511773A (ja) | 2004-04-15 |
| EP1327151A2 (en) | 2003-07-16 |
| CN1474944A (zh) | 2004-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020182649A1 (en) | Methods for protein identification, characterization and sequencing by tandem mass spectrometry | |
| US20020195555A1 (en) | Apparatus and methods for affinity capture tandem mass spectrometry | |
| US8633031B2 (en) | Expression quantification using mass spectrometry | |
| Yang et al. | Characterization of glycopeptides using a stepped higher‐energy C‐trap dissociation approach on a hybrid quadrupole orbitrap | |
| US11428696B2 (en) | Mass spectrometry analysis of mutant polypeptides in biological samples | |
| US20030219731A1 (en) | Methods for characterizing molecular interactions using affinity capture tandem mass spectrometry | |
| Nishikaze | Sensitive and structure-informative N-glycosylation analysis by MALDI-MS; ionization, fragmentation, and derivatization | |
| Mo et al. | Analytical aspects of mass spectrometry and proteomics | |
| US11726096B2 (en) | Fast protein sequencing | |
| CA2425456A1 (en) | Apparatus and methods for affinity capture tandem mass spectrometry | |
| WO2014121031A1 (en) | Characterization of antibody mixtures by mass spectrometry | |
| US20060078960A1 (en) | Expression quantification using mass spectrometry | |
| Matthiesen et al. | Introduction to mass spectrometry-based proteomics | |
| EP1735813A2 (en) | Identification of modified peptides by mass spectrometry | |
| EP1617224A1 (en) | De novo sequencing using tandem mass spectrometry | |
| US20080138909A1 (en) | Mass Spectrometry of Arginine-Containing Peptides | |
| Zhao et al. | Analysis of protein glycosylation and phosphorylation using liquid phase separation, protein microarray technology, and mass spectrometry | |
| JP2019052995A (ja) | 糖タンパク質における糖鎖の結合領域の同定方法およびキット | |
| DeSouza | Cancer Biomarker Discovery Using Mass Spectrometry | |
| Zhang | Method development of characterization of N-linked glycoproteins in mass spectrometry | |
| Wei et al. | Parallel Structural Characterization of Glycopeptides and Glycoprotein Quantification by Electrospray Quadrupole Ion-mobility Time-of-flight Mass Spectrometry with Ultra Performance Liquid Chromatography | |
| Arnott | Basics of TSQ/IT Mass Spectrometry: precursor, product, and neutral loss scanning. ESI and nanospray ionisation | |
| Claude et al. | LC/MALDI.• The chromatographic enhancement was evaluated by on-line nanoscale HPLC coupled with Electrospray on a Q-Tof PremierTM.• LC-MALDI/MS/MS analysis was also |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |